Cargando…

Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design

PURPOSE. Sodium glucose co-transporter 2 inhibitors (SGLT2i) remarkably reduced the incidence of hospitalization for heart failure and cardiovascular death of conservatively managed chronic kidney disease. We hypothesized that adding SGLT2i to standard treatment would yield cardiovascular benefits a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barreto, Joaquim, Martins, Marilia, Pascoa, Mauro, Medorima, Sheila T. K, Bonilha, Isabella, Jesus, Daniel Campos, Carbonara, Cinthia E. M., Quadros, Kelcia R. S., Assato, Barbara, Campos-Staffico, Alessandra M, Júnior, Gil Guerra, Nadruz, Wilson, de Oliveira, Rodrigo B., Sposito, Andrei C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602138/ https://www.ncbi.nlm.nih.gov/pubmed/37886458 http://dx.doi.org/10.21203/rs.3.rs-3434207/v1

Ejemplares similares

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
por: Barreto, Joaquim, et al.
Publicado: (2023)

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
por: Wolf, Vaneza Lira W., et al.
Publicado: (2021)

Dapagliflozin in patients with COVID-19: truth or dare
por: Rossello, Xavier, et al.
Publicado: (2021)

Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
por: Cintra, Riobaldo M. R., et al.
Publicado: (2019)

Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
por: Sposito, Andrei C., et al.
Publicado: (2021)

Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis
por: Barreto, Joaquim, et al.
Publicado: (2022)

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial
por: Breder, Ikaro, et al.
Publicado: (2020)

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
por: Kosiborod, Mikhail, et al.
Publicado: (2021)

Effect of aluminum accumulation on bone and cardiovascular risk in the current era
por: Carbonara, Cinthia E. M., et al.
Publicado: (2023)

AGEs accumulation is related to muscle degeneration and vascular calcification in peritoneal dialysis patients
por: Fonseca, Laís de Faria, et al.
Publicado: (2021)

Race and Place in ESKD
por: Watford, Daniel J., et al.
Publicado: (2020)

Very low HDL levels: clinical assessment and management
por: Bonilha, Isabella, et al.
Publicado: (2023)

Daring to Compete
por: Foreman, Diane
Publicado: (2019)

Dare to Serve
por: Bachelder, Cheryl
Publicado: (2018)

Dare to Serve
por: Bachelder, Cheryl
Publicado: (2015)

Dare to Create!
por: Boudon, Marie
Publicado: (2021)

Daring to Do
Publicado: (1861)

Daring to Do
Publicado: (1877)

Who dares, wins?
por: Kim, Tae-Il
Publicado: (2016)

Dare we hope
por: McAlister, Vivian
Publicado: (2021)

A Daring Therapeutist
Publicado: (1878)

Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction
por: Sposito, Andrei C., et al.
Publicado: (2019)

Dare, Dream, Do: Remarkable Things Happen When You Dare to Dream
por: Johnson, Whitney
Publicado: (2013)

The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus
por: Bonilha, Isabella, et al.
Publicado: (2021)

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
por: Sposito, Andrei C., et al.
Publicado: (2022)

Te dare la tierra/
por: Llorens, Chufo 1931-
Publicado: (2010)

DARE: (a)Live and kicking!
por: Lilian van der Vaart
Publicado: (2004)

Editorial: Daring to Speak Out
por: Golightley, Malcom, et al.
Publicado: (2016)

Advanced Glycation End Products and Bone Metabolism in Patients with Chronic Kidney Disease
por: Quadros, Kélcia R. S., et al.
Publicado: (2023)

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
por: Kosiborod, Mikhail N, et al.
Publicado: (2021)

Omega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction
por: Campos-Staffico, Alessandra M., et al.
Publicado: (2019)

Renal osteodystrophy and clinical outcomes: data from the Brazilian Registry of Bone Biopsies - REBRABO
por: Carbonara, Cinthia Esbrile Moraes, et al.
Publicado: (2020)

Ecological momentary assessment of fatigue, sleepiness, and exhaustion in ESKD
por: Abdel-Kader, Khaled, et al.
Publicado: (2014)

Pre-ESKD Nephrology Care and Employment at the Start of Dialysis
por: Awan, Ahmed A., et al.
Publicado: (2020)

Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD
por: Srivastava, Anand, et al.
Publicado: (2021)

COVAN Leading to ESKD Despite Minimal COVID Symptoms
por: Maldonado, Dawn, et al.
Publicado: (2022)

Kidney Health Initiative ESKD Data Standards Project
por: Dalrymple, Lorien S., et al.
Publicado: (2022)

1.Implementation: the FAIR and DARE experience
por: Chris Awre and Lilian van der Vaart
Publicado: (2004)

Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
por: Nogueira, Ana Claudia Cavalcante, et al.
Publicado: (2023)

Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?
por: Assi, Rita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j5gn594gjlavjaceq2so4gld74